



## Soleno Therapeutics to Present at Upcoming February Investor Conferences

February 1, 2024 1:00 PM EST

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences:

Guggenheim Healthcare Talks | 6<sup>th</sup> Annual Biotechnology Conference  
Thursday, February 8, 2024, at 2:30 PM Eastern Time

34<sup>th</sup> Annual Oppenheimer Healthcare Life Sciences Conference  
Wednesday, February 14, 2024, at 11:20 AM Eastern Time

Anish Bhatnagar, M.D., Chief Executive Officer, will also be participating in a fireside chat, hosted by Dr. Leland Gershell.

A live audio webcast and replays of the presentations will be available in the Investors section on the Company's website at [www.solenolife.com](http://www.solenolife.com).

### **About Soleno Therapeutics, Inc.**

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit [www.solenolife.com](http://www.solenolife.com).

### **Corporate Contact:**

Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics